Darren W Davis
Overview
Explore the profile of Darren W Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le Du F, Fujii T, Kida K, Davis D, Park M, Liu D, et al.
PLoS One
. 2020 Mar;
15(3):e0229903.
PMID: 32214335
Background: Tumor cells with a mesenchymal phenotype and/or cancer stem-like cells (CSCs) are known to contribute to metastasis and drug resistance. Circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition (EMT) and...
2.
Lim B, Murthy R, Lee J, Jackson S, Iwase T, Davis D, et al.
Br J Cancer
. 2019 May;
120(12):1105-1112.
PMID: 31097774
Background: Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops. In a preclinical model,...
3.
Rugo H, Cortes J, Awada A, OShaughnessy J, Twelves C, Im S, et al.
Clin Cancer Res
. 2018 Apr;
24(14):3348-3357.
PMID: 29618616
Preplanned exploratory analyses were performed to identify biomarkers in circulating tumor cells (CTC) predictive of response to the topoisomerase 1 inhibitor etirinotecan pegol (EP). The BEACON trial treated patients with...
4.
OShannessy D, Davis D, Anderes K, Somers E
Biomark Insights
. 2016 Feb;
11:7-18.
PMID: 26848256
This study describes our efforts to further the field of noninvasive diagnostics, specifically in the area of liquid biopsies in oncology. We employed laser scanning cytometry using highly selective antibodies...
5.
Hong D, Garrido-Laguna I, Ekmekcioglu S, Falchook G, Naing A, Wheler J, et al.
Cancer
. 2014 Apr;
120(14):2164-73.
PMID: 24752867
Background: The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothelial growth factor (VEGF) pathway with combined bevacizumab and cediranib (a...
6.
Gupta V, Jafferji I, Garza M, Melnikova V, Hasegawa D, Pethig R, et al.
Biomicrofluidics
. 2013 Jun;
6(2):24133.
PMID: 23805171
Isolation and enumeration of circulating tumor cells (CTCs) are used to monitor metastatic disease progression and guide cancer therapy. However, currently available technologies are limited to cells expressing specific cell...
7.
Amato R, Melnikova V, Zhang Y, Liu W, Saxena S, Shah P, et al.
Urology
. 2013 Apr;
81(6):1303-7.
PMID: 23622774
Objective: To assess the use of circulating tumor cells (CTCs) as a longitudinal endpoint factor for clinical monitoring of patients with prostate cancer and to evaluate the association among the...
8.
de Souza J, Davis D, Zhang Y, Khattri A, Seiwert T, Aktolga S, et al.
Clin Cancer Res
. 2012 Feb;
18(8):2336-43.
PMID: 22371453
Purpose: This study sought to determine the efficacy and safety profile of lapatinib in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Experimental Design: This phase...
9.
Cohen E, Davis D, Karrison T, Seiwert T, Wong S, Nattam S, et al.
Lancet Oncol
. 2009 Feb;
10(3):247-57.
PMID: 19201650
Background: Epidermal growth factor receptor (EGFR) is a validated target in squamous-cell carcinoma of the head and neck, but in patients with recurrent or metastatic disease, EGFR targeting agents have...
10.
Tellez C, Davis D, Prieto V, Gershenwald J, Johnson M, McCarty M, et al.
J Invest Dermatol
. 2006 Sep;
127(2):387-93.
PMID: 16946713
The identification of molecular markers of melanoma progression is needed to more accurately stage and identify treatments for patients with malignant melanoma. Previously, we demonstrated that loss of the activator...